Competition Patients Pharmaceutical manufacturing 
European Pharmaceutical Review
DECEMBER 4, 2023
To address these issues, companies should adopt more advanced production strategies such as continuous flow chemistry, as they can shorten manufacturing processes, increase productivity and throughput. Simultaneously, there is increasing need for stringent quality control and traceability throughout the supply chain to ensure patient safety.
World of DTC Marketing
APRIL 12, 2021
QUICK READ: Pharma supply chain issues are a concern for us all but especially patients. Patients should be scared. We need a 21st-century approach that puts patient safety first. The adulterated product was found to have caused nine patient deaths and 574 serious adverse events (SAEs). In other words, money over safety.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
European Pharmaceutical Review
AUGUST 29, 2024
A major new £400 million public-private collaboration has launched in the UK, aimed at enhancing the life sciences sector’s economic growth and the competitiveness over the next five years. The innovative programme is set to strengthen clinical trials and improve medicine manufacturing in the UK.
Impetus Digital
AUGUST 2, 2024
The pharmaceutical industry has numerous use cases for AI. From the drug discovery phase to patient care, AI has the potential to enhance almost every stage of the product life cycle. It’s remarkable to see the progress made in the technology compared to only a few months ago and there are no signs of the progress slowing down.
European Pharmaceutical Review
SEPTEMBER 29, 2022
The US Food and Drug Administration (FDA)’s Center for Drug Evaluation and Research (CDER) through the Office of Pharmaceutical Quality in 2021 embarked on an initiative to develop a framework for establishing a pharmaceutical manufacturing site quality rating system, the Quality management maturity (QMM) programme.
European Pharmaceutical Review
NOVEMBER 8, 2022
Pharmaceutical manufacturers have submitted Citizen Petitions raising safety or efficacy concerns about proposed competing generic and biosimilar products, and such submissions often delay FDA approval of the proposed products while the FDA resolves the pending petitions. Conclusion.
pharmaphorum
NOVEMBER 25, 2022
Having a healthy and sustainable pharmaceutical sector is both a necessary requirement and a good one for society. Talking about the integrated supply chain that is always in play with France and Germany, he warned of continuous competition that could pose a gradual risk to Italy’s research basis in development research.
Expert insights. Personalized for you.
105 
Let's personalize your content